Idiopathic pulmonary fibrosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(18 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Idiopathic pulmonary fibrosis }}
{{Idiopathic pulmonary fibrosis }}
{{CMG}}
{{CMG}}; {{AE}} {{AEL}}  
==Overview==
==Overview==
Pulmonary [[fibrosis]] share the pathogenesis process of interstitial lung disease which involve the pulmonary [[parenchyma]]. Although the exact pathogenesis is not fully understood, there are many initiating factors which cause the pulmonary tissue injury. The primary features of the lung injury includes [[inflammation]], [[fibrosis]], and [[granulomas]] development.
==Pathophysiology==
==Pathophysiology==
Pulmonary fibrosis has often been called an [[autoimmunity|autoimmune disease]].  However, it is perhaps better characterized as an abnormal and excessive deposition of fibrotic tissue in the pulmonary interstitium with minimal associated inflammation.<ref name="Selman">{{cite journal |last=Selman |first=Moisés |coauthors=Talmadge E. King, Jr.; and Annie Pardo |title=Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy |journal=Annals of Internal Medicine |year=2001 |volume=134 |number=2 |pages=136-51 |url=http://www.annals.org/cgi/content/abstract/134/2/136}}</ref>  [[Autoantibodies]], a hallmark of autoimmune diseases, are found in a minority of patients with truly idiopathic pulmonary fibrosis.  Moreover, many autoimmune diseases associated with "pulmonary fibrosis", such as scleroderma, are more frequently associated with a related but more inflammatory disease, nonspecific interstitial pneumonitis.<ref>{{cite journal |last=King, Jr. |first=Talmadge E. |title=Centennial review: clinical advances in the diagnosis and therapy of the interstitial lung diseases |url=http://ajrccm.atsjournals.org/cgi/content/full/172/3/268 |journal=American Journal of Respiratory and Critical Care Medicine |year=2005 |volume=172 |number=3 |pages=268-79}}</ref> It is associated with [[smoking]]<ref>{{cite journal |last=Nagai |first=Sonoko |coauthors=Yuma Hoshino, Michio Hayashi, Isao Ito |title=Smoking-related interstitial lung diseases |url=http://www.co-pulmonarymedicine.com/pt/re/copulmonary/abstract.00063198-200009000-00005.htm |journal=Current Opinion in Pulmonary Medicine |volume=6 |issue=5 |pages=415-9 |year=2000 |pmid=10958232}}</ref> and exhibits some dependency on the amount of smoking.<ref>{{cite journal |last=Baumgartner |first=KB |coauthors=Samet JM, Stidley CA, Colby TV, Waldron JA |title=Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis |url= http://ajrccm.atsjournals.org/cgi/content/short/155/1/242 |journal=American Journal of Respiratory and Critical Care Medicine |volume=155 |number=1 |pages=242-248 |year=1997 |pmid=9001319}}</ref>


==Pathology==
=== Normal lung tissue ===
;Histology
* Lungs are composed normally of extracellular collagen which allows the lungs to exert their breathing efforts.
{{main article|Usual interstitial pneumonia}}
* Different collagen types in the lung include the following:<ref name="pmid1916105">{{cite journal| author=van der Rest M, Garrone R| title=Collagen family of proteins. | journal=FASEB J | year= 1991 | volume= 5 | issue= 13 | pages= 2814-23 | pmid=1916105 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1916105  }}</ref>
** Type 1 and type 3 compose majority of the lung tissue
** Type 2 is the primary component of the cartilage of the main bronchi
** Type 4 forms the basement membrane
** Type 5 forms the interstitial tissue 
* Normally, collagen is degraded and produced regularly to preserve the normal lung tissue.<ref name="pmid7150261">{{cite journal| author=Laurent GJ| title=Rates of collagen synthesis in lung, skin and muscle obtained in vivo by a simplified method using [3H]proline. | journal=Biochem J | year= 1982 | volume= 206 | issue= 3 | pages= 535-44 | pmid=7150261 | doi= | pmc=1158621 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7150261  }}</ref> 
* Collagen is produced by fibroblasts which also can degrade some of the collagen produced. 
* [[Metalloproteinase|Metalloproteinases]] produced by [[fibroblasts]], [[neutrophils]], and [[macrophages]] plays a primary role in degradation of collagen. 


[[Image:Usual interstitial pneumonia (1).JPG|left|200px|thumb|[[Micrograph]] of usual interstitial pneumonia (UIP). UIP most often represents '''idiopathic pulmonary fibrosis'''. [[H&E stain]]. [[Autopsy]] specimen.]]
===Pathogenesis===
*Interstitial lung disease is a group of disorders that involve pulmonary [[parenchyma]].
*The exact pathogenesis of these disorders is not fully understood.
*There are multiple initiating factors that cause [[pulmonary]] injury. However, immunopathogenic responses of [[lung]] tissue are quite similar.
*There are two major histopathologic patterns in response to [[lung]] injury which include:
**[[Inflammation]] and [[fibrosis]] pattern
**[[Granulomatous]] pattern
<br>
<div style="text-align: center;">'''Algorithm showing pathophysiology of Interstitial Lung Disease'''<ref name="pmid25726561">{{cite journal| author=Bagnato G, Harari S| title=Cellular interactions in the pathogenesis of interstitial lung diseases. | journal=Eur Respir Rev | year= 2015 | volume= 24 | issue= 135 | pages= 102-14 | pmid=25726561 | doi=10.1183/09059180.00003214 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25726561  }} </ref></div>


[[Histology|Histologic]] specimens for the diagnosis of IPF must be large enough that the pathologist can comment on the underlying lung architecture. 


Small biopsies, such as those obtained via transbronchial lung biopsy (performed during [[bronchoscopy]]) are generally not sufficient for this purposeHence, larger biopsies obtained surgically via a thoracotomy or thoracoscopy are usually necessary.<ref name=ATS2/>
{{Family tree/start}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | T01 | | | | | | | | | | | | T01=[[Tissue]] injury in [[lungs]]}}
{{Family tree| | | | | | | | | | | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | S01 | | | | | | | | | | S02 | | | | | | | S01=[[Parenchymal]] injury|S02=[[Vascular]] injury}}
{{Family tree| | | | | | | | | | | | | | | | | |!| | | | | | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | R01 | | | | | | | |!| | | | | | | | | | | R02 | | | | | | | R01=[[Mast cell]]s in [[lungs]] in response to tissue injury|R02= LPA6, LPA2, and LPA4 receptors<ref name="pmid23084965">{{cite journal| author=Ren Y, Guo L, Tang X, Apparsundaram S, Kitson C, Deguzman J et al.| title=Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells. | journal=Microvasc Res | year= 2013 | volume= 85 | issue=  | pages= 59-67 | pmid=23084965 | doi=10.1016/j.mvr.2012.10.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23084965  }} </ref>}}
{{Family tree| | | | | | |,|-|^|-|.| | | | | | |!| | | | | | | | | |,|-|^|-|.| | | | | | }}
{{Family tree| | Q01 | | Q06 | | Q03 | | | | | Q02 | | | | | | | | Q04 | | Q05 | | | | | Q01=Decreased [[Secreted frizzled-related protein 1|sFRP-1 (secreted frizzled-related protein 1)]] in [[fibroblasts]]<ref name="pmid21360508">{{cite journal| author=Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA| title=Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. | journal=Arthritis Rheum | year= 2011 | volume= 63 | issue= 3 | pages= 783-94 | pmid=21360508 | doi=10.1002/art.30159 | pmc=3139818 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21360508  }} </ref>|Q02= [[Insulin-like growth factor]] ([[IGF]]) signalling<ref name="pmid21360508">{{cite journal| author=Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA| title=Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. | journal=Arthritis Rheum | year= 2011 | volume= 63 | issue= 3 | pages= 783-94 | pmid=21360508 | doi=10.1002/art.30159 | pmc=3139818 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21360508  }} </ref>|Q03=[[Transforming growth factor-β]] ([[TGF-β]])<ref name="pmid19926870">{{cite journal| author=Andersson CK, Mori M, Bjermer L, Löfdahl CG, Erjefält JS| title=Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease. | journal=Am J Respir Crit Care Med | year= 2010 | volume= 181 | issue= 3 | pages= 206-17 | pmid=19926870 | doi=10.1164/rccm.200906-0932OC | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19926870  }} </ref>|Q04= Reduced expression of angiogenic factors,<br>[[vascular endothelial growth factor]] (VEGF)<ref name="pmid14754760">{{cite journal| author=Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M et al.| title=Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. | journal=Am J Respir Crit Care Med | year= 2004 | volume= 169 | issue= 11 | pages= 1203-8 | pmid=14754760 | doi=10.1164/rccm.200308-1111OC | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14754760  }} </ref>|Q05=Elevation of angiostatic factors,<br>pigment epithelium-derived factor<ref name="pmid15117744">{{cite journal| author=Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE, Geraci MW et al.| title=Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. | journal=Am J Respir Crit Care Med | year= 2004 | volume= 170 | issue= 3 | pages= 242-51 | pmid=15117744 | doi=10.1164/rccm.200308-1151OC | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15117744  }} </ref>|Q06=Secretes [[tryptase]]}}
{{Family tree| | |!| | | |!| | | |!| | | |,|-|-|^|-|-|.| | | | | | |`|-|v|-|'| | | | | | }}
{{Family tree| | P01 | | P02 | | P05 | | P04 | | | | P03 |.| | | | | | P06 | | | | | P01=[[Wnt signaling pathway|Wnt/β-catenin signalling pathway]]<ref name="pmid18478089">{{cite journal| author=Königshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, Seeger W et al.| title=Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. | journal=PLoS One | year= 2008 | volume= 3 | issue= 5 | pages= e2142 | pmid=18478089 | doi=10.1371/journal.pone.0002142 | pmc=2374879 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18478089  }} </ref><ref name="pmid21454805">{{cite journal| author=Lam AP, Flozak AS, Russell S, Wei J, Jain M, Mutlu GM et al.| title=Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. | journal=Am J Respir Cell Mol Biol | year= 2011 | volume= 45 | issue= 5 | pages= 915-22 | pmid=21454805 | doi=10.1165/rcmb.2010-0113OC | pmc=3262680 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21454805  }} </ref>|P02=PAR-2/protein kinase (PK)C-α/Raf-1/p44/42 signaling pathway<ref name="pmid23562441">{{cite journal| author=Wygrecka M, Dahal BK, Kosanovic D, Petersen F, Taborski B, von Gerlach S et al.| title=Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-α/Raf-1/p44/42 signaling pathway. | journal=Am J Pathol | year= 2013 | volume= 182 | issue= 6 | pages= 2094-108 | pmid=23562441 | doi=10.1016/j.ajpath.2013.02.013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23562441  }} </ref>|P03=[[IGFBP3|IGF-binding protein 3 (IGFBP-3]])|P04=[[Insulin-like growth factor binding protein|IGF-binding protein 5 (IGFBP-5)]]<ref name="pmid21511034">{{cite journal| author=Bhattacharyya S, Wu M, Fang F, Tourtellotte W, Feghali-Bostwick C, Varga J| title=Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. | journal=Matrix Biol | year= 2011 | volume= 30 | issue= 4 | pages= 235-42 | pmid=21511034 | doi=10.1016/j.matbio.2011.03.005 | pmc=3135176 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21511034 }} </ref>|P05=Upregulation of Egr-1 (early growth response protein 1)<ref name="pmid19628764">{{cite journal| author=Yasuoka H, Hsu E, Ruiz XD, Steinman RA, Choi AM, Feghali-Bostwick CA| title=The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms. | journal=Am J Pathol | year= 2009 | volume= 175 | issue= 2 | pages= 605-15 | pmid=19628764 | doi=10.2353/ajpath.2009.080991 | pmc=2716960 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19628764  }} </ref>|P06=Loss of [[endothelial]] barrier function }}
{{Family tree| |!| |!| | |!| | | |!| | | |!| | | | | |!| |!| | | | | | |!| | | | | | | | }}
{{Family tree| O01 |!| | |!| | | |`|-|-|-|^|.| | | | |!| O02 | | | | | |!| | | | | | | | O01=Dysregulation of repair in [[lung tissue]]  and activation of [[fibroblasts]]<ref name="pmid23881674">{{cite journal| author=Sun Z, Gong X, Zhu H, Wang C, Xu X, Cui D et al.| title=Inhibition of Wnt/β-catenin signaling promotes engraftment of mesenchymal stem cells to repair lung injury. | journal=J Cell Physiol | year= 2014 | volume= 229 | issue= 2 | pages= 213-24 | pmid=23881674 | doi=10.1002/jcp.24436 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23881674  }} </ref>|O02=Regulates [[transforming growth factor-β]] ([[TGF-β]]) }}
{{Family tree| | | |!| | |!| | | | | | | | |!| | | | |!|,|'| | | | | | |!| | | | | | | | }}
{{Family tree| | | |!| | |!| | | | | | | | |!| | | | A02 | | | | | | | |!| | | | | | | | A01=|A02=Induction of [[syndecan-2|syndecan-2 (SDC2)]]<ref name="pmid22900087">{{cite journal| author=Ruiz XD, Mlakar LR, Yamaguchi Y, Su Y, Larregina AT, Pilewski JM et al.| title=Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. | journal=PLoS One | year= 2012 | volume= 7 | issue= 8 | pages= e43049 | pmid=22900087 | doi=10.1371/journal.pone.0043049 | pmc=3416749 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22900087  }} </ref>}}
{{Family tree| | | |!| | |!| | | | | | | | |!| | | | |!| | | | | | | | |!| | | | | | | | }}
{{Family tree| | | |!| | |`|-|-|-|-|-|-|-|.|!|,|-|-|-|'| | | | | | | | |!| | | | | | | | }}
{{Family tree| | | |`|-|-|-|-|-|-|-|-|-|-| B01 | | | | | | | | | | | | |!| | | | | | | | B01=Activation,proliferation, and migration of [[fibroblast]] to the site of injury}}
{{Family tree| | | | | | | | | | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | C01 | | | | | | | | | | | | |!| | | | | | | | C01=[[Fibroblasts]]}}
{{Family tree| | | | | | | | | | | | |,|-|-|+|-|-|.| | | | | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | D01 | |!| | D02 | | | | | | | | | |!| | | | | | | | D01=Altered PTEN (phosphatase and tensin homologue)/Akt axis|D02=Acquire contractile stress fibres}}
{{Family tree| | | | | | | | | | | | |!| | |!| | |!| | | | | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | G01 | |!| | G02 | | G03 | | | | | |!| | | | | | | | G01= Inactivates [[FOX proteins|Fox (forkhead box) O3a]]<ref name="pmid23580232">{{cite journal| author=Nho RS, Peterson M, Hergert P, Henke CA| title=FoxO3a (Forkhead Box O3a) deficiency protects Idiopathic Pulmonary Fibrosis (IPF) fibroblasts from type I polymerized collagen matrix-induced apoptosis via caveolin-1 (cav-1) and Fas. | journal=PLoS One | year= 2013 | volume= 8 | issue= 4 | pages= e61017 | pmid=23580232 | doi=10.1371/journal.pone.0061017 | pmc=3620276 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23580232  }} </ref>|G02=Protomyofibroblast, composed of cytoplasmic [[actins]]|G03=[[Pleural]] [[mesothelial]] cells (PMCs)<ref name="pmid21737551">{{cite journal| author=Mubarak KK, Montes-Worboys A, Regev D, Nasreen N, Mohammed KA, Faruqi I et al.| title=Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. | journal=Eur Respir J | year= 2012 | volume= 39 | issue= 1 | pages= 133-40 | pmid=21737551 | doi=10.1183/09031936.00141010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21737551  }} </ref><ref name="pmid19411308">{{cite journal| author=Nasreen N, Mohammed KA, Mubarak KK, Baz MA, Akindipe OA, Fernandez-Bussy S et al.| title=Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. | journal=Am J Physiol Lung Cell Mol Physiol | year= 2009 | volume= 297 | issue= 1 | pages= L115-24 | pmid=19411308 | doi=10.1152/ajplung.90587.2008 | pmc=2711818 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19411308  }} </ref>}}
{{Family tree| | | | | | | | | | | | |!| | |!| | |!| | | |!| | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | H01 | |!| | H02 | | H03 | | | | | |!| | | | | | | | H01= Downregulation of [[Caveolin 1|caveolin-1 (cav-1)]] and Fas expression<ref name="pmid18759267">{{cite journal| author=Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP et al.| title=Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. | journal=Arthritis Rheum | year= 2008 | volume= 58 | issue= 9 | pages= 2854-65 | pmid=18759267 | doi=10.1002/art.23791 | pmc=2770094 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18759267  }} </ref>|H02=De novo expression of α-smooth muscle actin (α-SMA)|H03=TGF-β1-dependent mesothelial–mesenchymal transition}}
{{Family tree| | | | | | | | | | | | |!| | |!| | | |!| |!| | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | I01 | |!| | | | I02 | | | | | | | |!| | | | | | | | I01=[[Fibroblast]] resistant to [[apoptosis]]<ref name="pmid16738200">{{cite journal| author=Thannickal VJ, Horowitz JC| title=Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. | journal=Proc Am Thorac Soc | year= 2006 | volume= 3 | issue= 4 | pages= 350-6 | pmid=16738200 | doi=10.1513/pats.200601-001TK | pmc=2231523 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16738200  }} </ref>|I02=[[Myofibroblasts]]<ref name="pmid11988769">{{cite journal| author=Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA| title=Myofibroblasts and mechano-regulation of connective tissue remodelling. | journal=Nat Rev Mol Cell Biol | year= 2002 | volume= 3 | issue= 5 | pages= 349-63 | pmid=11988769 | doi=10.1038/nrm809 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11988769  }} </ref>}}
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| |!| | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| |)|-|-|-|-|.| | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| J02 | | | J03 | |!| | | | | | | | J02=Different ranges of contractions mediated by RhoA/Rho-associated kinase|J03=Changes in intracellular calcium concentrations}}
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| | |`|-|v|-|'| | |!| | | | | | | | }}
{{Family tree| | | | | | | | K01 | | | | | |!| |,|-|'| | | | K02 | | | |!| | | | | K03 | K01=Recruitement of fibrocytes in [[lungs]]|K02=Lock step mechanism of cyclic and contractile events<ref name="pmid20427321">{{cite journal| author=Castella LF, Buscemi L, Godbout C, Meister JJ, Hinz B| title=A new lock-step mechanism of matrix remodelling based on subcellular contractile events. | journal=J Cell Sci | year= 2010 | volume= 123 | issue= Pt 10 | pages= 1751-60 | pmid=20427321 | doi=10.1242/jcs.066795 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20427321  }} </ref>|K03=[[T helper cell|T-helper cell type 2]] on site of injury<ref name="pmid15802346">{{cite journal| author=Capelli A, Di Stefano A, Gnemmi I, Donner CF| title=CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. | journal=Eur Respir J | year= 2005 | volume= 25 | issue= 4 | pages= 701-7 | pmid=15802346 | doi=10.1183/09031936.05.00082604 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15802346  }} </ref><ref name="pmid15383605">{{cite journal| author=Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM et al.| title=The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. | journal=J Immunol | year= 2004 | volume= 173 | issue= 7 | pages= 4692-8 | pmid=15383605 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15383605  }} </ref>}}
{{Family tree| | | | | | | | |!| | | | | | |!| |!| | | | | | |!| | | | |!| | | | | |!| | }}
{{Family tree| | | | | | | | L01 | | | | | | L02 | | | | | | L03 | | | |!| | | | | L04 | |L01=Upregulation of [[CXCR4|C-X-C chemokine receptor type 4 (CXCR4)]]<br>on [[fibrocytes]] and its ligand<br>CXCL12 (stromal cell-derived factor 1)<ref name="pmid18374622">{{cite journal| author=Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A et al.| title=Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. | journal=Int J Biochem Cell Biol | year= 2008 | volume= 40 | issue= 10 | pages= 2129-40 | pmid=18374622 | doi=10.1016/j.biocel.2008.02.012 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18374622  }} </ref>|L02=Excess extracellular matrix production|L03=Exerting traction force|L04=[[Interleukin-13]]}}
{{Family tree| | | | | | | | |!| | | | | | | |!|,|-|-|-|-|-|-|'| | | | |!| | | | | |!| | }}
{{Family tree| | | | | | | | M01 | | | | | | M02 | | | | | | | | | | | |!| | | | | M03 | |M01=Migration of fibrocytes to the site of injury<ref name="pmid15743780">{{cite journal| author=Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C et al.| title=CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. | journal=Am J Pathol | year= 2005 | volume= 166 | issue= 3 | pages= 675-84 | pmid=15743780 | doi=10.1016/S0002-9440(10)62289-4 | pmc=1780139 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15743780  }} </ref>|M02=Tissue remodelling<ref name="pmid17525249">{{cite journal| author=Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G| title=The myofibroblast: one function, multiple origins. | journal=Am J Pathol | year= 2007 | volume= 170 | issue= 6 | pages= 1807-16 | pmid=17525249 | doi=10.2353/ajpath.2007.070112 | pmc=1899462 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17525249  }} </ref>|M03=Alternate pathway activation of [[macrophages]]<ref name="pmid7995399">{{cite journal| author=Lohmann-Matthes ML, Steinmüller C, Franke-Ullmann G| title=Pulmonary macrophages. | journal=Eur Respir J | year= 1994 | volume= 7 | issue= 9 | pages= 1678-89 | pmid=7995399 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7995399  }} </ref>}}
{{Family tree| | | | | | | | |!| | | | | | | |!| | | | | | | | | | | | |!| | | | | |!| | }}
{{Family tree| | | | | | | | |`|-|-|-|-|-|-|.|!|,|-|-|-|-|-|-|-|-|-|-|-|'| | | | | |!| | }}
{{Family tree| | | | | | | | | | | | | | | | N01 |-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|'| N01=Lung Fibrosis}}
{{Family tree/end}}


The histological pattern of fibrosis associated with '''IPF''' is referred to as usual interstitial pneumonia (UIP).  
==Gross pathology==
* The most important characteristics of idiopathic pulmonary fibrosis on gross pathology include:<ref name="pmid24050627">{{cite journal| author=Wolters PJ, Collard HR, Jones KD| title=Pathogenesis of idiopathic pulmonary fibrosis. | journal=Annu Rev Pathol | year= 2014 | volume= 9 | issue=  | pages= 157-79 | pmid=24050627 | doi=10.1146/annurev-pathol-012513-104706 | pmc=4116429 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24050627  }}</ref>
** Inferior lobes [[fibrosis]]
** Cobblestone appearance of the [[pleura]]
** Honeycomb appearance of the [[lung]] 
** Air-spaces enlargement
** [[Fibrosis|Fibrotic]] retraction of the [[airways]]


Although '''UIP''' is required for the diagnosis of '''IPF''', it can be seen in other diseases as well.<ref>{{cite book |title=Robbins and Cotran's Pathological Basis of Disease |edition=7th ed. |first=Vinay |last=Kumar |coauthors=Nelso Fausto and Abul Abbas |year=2005 |publisher=Saunders |isbn=978-0721601878 |pages=729}}</ref>
[[Image:Honeycomb-lung-gross-pathology-1.jpg|350px|thumb|center|Honeycomb appearance of a fibrotic lung.<br>Source: Case courtesy of A.Prof Frank Gaillard, rID: 8621, via www.radiopaedia.org]]


Key features of UIP include fibroblast foci, a pattern of temporal heterogeneity, dense interstitial fibrosis in a paraseptal and subpleural distribution, and a relatively mild or minor component of interstitial chronic inflammation.<ref name=ATS2/> To help narrow the differential diagnosis, an absence of significant [[granuloma|granulomatous]] inflammation, [[microorganism]]s, [[eosinophil]]s, and [[asbestosis|asbestos bodies]] is required.
==Microscopic pathology==
* The microscopic feature associated with idiopathic pulmonary fibrosis is named as "[[usual interstitial pneumonia]] (UIP)".<ref name="pmid11519507">{{cite journal| author=Gross TJ, Hunninghake GW| title=Idiopathic pulmonary fibrosis. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 7 | pages= 517-25 | pmid=11519507 | doi=10.1056/NEJMra003200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11519507  }}</ref>
* The histologic findings in UIP include the following:
** [[Proliferation]] of [[Mesenchymal cell|mesenchymal cells]]  
** Areas of different [[fibrosis]] degree
** Dense deposition of [[collagen]] fibers
** Overproduction of [[extracellular matrix]]  
** Poor differentiated pulmonary architecture
** Honeycomb cysts (sub-pleural cysts)


==References==
==References==
Line 26: Line 93:
{{WH}}
{{WH}}
{{WS}}
{{WS}}


[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Disease]]
[[Category:Medicine]]
[[Category:Up-To-Date]]
[[Category:Primary Care]

Latest revision as of 18:40, 9 April 2018

Idiopathic pulmonary fibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Idiopathic pulmonary fibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic pulmonary fibrosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Idiopathic pulmonary fibrosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Idiopathic pulmonary fibrosis pathophysiology

CDC on Idiopathic pulmonary fibrosis pathophysiology

Idiopathic pulmonary fibrosis pathophysiology in the news

Blogs on Idiopathic pulmonary fibrosis pathophysiology

Directions to Hospitals Treating Idiopathic pulmonary fibrosis

Risk calculators and risk factors for Idiopathic pulmonary fibrosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Pulmonary fibrosis share the pathogenesis process of interstitial lung disease which involve the pulmonary parenchyma. Although the exact pathogenesis is not fully understood, there are many initiating factors which cause the pulmonary tissue injury. The primary features of the lung injury includes inflammation, fibrosis, and granulomas development.

Pathophysiology

Normal lung tissue

  • Lungs are composed normally of extracellular collagen which allows the lungs to exert their breathing efforts.
  • Different collagen types in the lung include the following:[1]
    • Type 1 and type 3 compose majority of the lung tissue
    • Type 2 is the primary component of the cartilage of the main bronchi
    • Type 4 forms the basement membrane
    • Type 5 forms the interstitial tissue
  • Normally, collagen is degraded and produced regularly to preserve the normal lung tissue.[2]
  • Collagen is produced by fibroblasts which also can degrade some of the collagen produced.
  • Metalloproteinases produced by fibroblasts, neutrophils, and macrophages plays a primary role in degradation of collagen.

Pathogenesis

  • Interstitial lung disease is a group of disorders that involve pulmonary parenchyma.
  • The exact pathogenesis of these disorders is not fully understood.
  • There are multiple initiating factors that cause pulmonary injury. However, immunopathogenic responses of lung tissue are quite similar.
  • There are two major histopathologic patterns in response to lung injury which include:


Algorithm showing pathophysiology of Interstitial Lung Disease[3]


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue injury in lungs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parenchymal injury
 
 
 
 
 
 
 
 
 
Vascular injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mast cells in lungs in response to tissue injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LPA6, LPA2, and LPA4 receptors[4]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Decreased sFRP-1 (secreted frizzled-related protein 1) in fibroblasts[5]
 
Secretes tryptase
 
Transforming growth factor-β (TGF-β)[6]
 
 
 
 
Insulin-like growth factor (IGF) signalling[5]
 
 
 
 
 
 
 
Reduced expression of angiogenic factors,
vascular endothelial growth factor (VEGF)[7]
 
Elevation of angiostatic factors,
pigment epithelium-derived factor[8]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wnt/β-catenin signalling pathway[9][10]
 
PAR-2/protein kinase (PK)C-α/Raf-1/p44/42 signaling pathway[11]
 
Upregulation of Egr-1 (early growth response protein 1)[12]
 
IGF-binding protein 5 (IGFBP-5)[13]
 
 
 
IGF-binding protein 3 (IGFBP-3)
 
 
 
 
 
 
 
Loss of endothelial barrier function
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dysregulation of repair in lung tissue and activation of fibroblasts[14]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulates transforming growth factor-β (TGF-β)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Induction of syndecan-2 (SDC2)[15]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activation,proliferation, and migration of fibroblast to the site of injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibroblasts
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altered PTEN (phosphatase and tensin homologue)/Akt axis
 
 
 
 
Acquire contractile stress fibres
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inactivates Fox (forkhead box) O3a[16]
 
 
 
 
Protomyofibroblast, composed of cytoplasmic actins
 
Pleural mesothelial cells (PMCs)[17][18]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Downregulation of caveolin-1 (cav-1) and Fas expression[19]
 
 
 
 
De novo expression of α-smooth muscle actin (α-SMA)
 
TGF-β1-dependent mesothelial–mesenchymal transition
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibroblast resistant to apoptosis[20]
 
 
 
 
 
 
Myofibroblasts[21]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Different ranges of contractions mediated by RhoA/Rho-associated kinase
 
 
Changes in intracellular calcium concentrations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitement of fibrocytes in lungs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lock step mechanism of cyclic and contractile events[22]
 
 
 
 
 
 
 
 
 
T-helper cell type 2 on site of injury[23][24]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upregulation of C-X-C chemokine receptor type 4 (CXCR4)
on fibrocytes and its ligand
CXCL12 (stromal cell-derived factor 1)[25]
 
 
 
 
 
Excess extracellular matrix production
 
 
 
 
 
Exerting traction force
 
 
 
 
 
 
 
 
 
Interleukin-13
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Migration of fibrocytes to the site of injury[26]
 
 
 
 
 
Tissue remodelling[27]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alternate pathway activation of macrophages[28]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lung Fibrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Gross pathology

  • The most important characteristics of idiopathic pulmonary fibrosis on gross pathology include:[29]
Honeycomb appearance of a fibrotic lung.
Source: Case courtesy of A.Prof Frank Gaillard, rID: 8621, via www.radiopaedia.org

Microscopic pathology

References

  1. van der Rest M, Garrone R (1991). "Collagen family of proteins". FASEB J. 5 (13): 2814–23. PMID 1916105.
  2. Laurent GJ (1982). "Rates of collagen synthesis in lung, skin and muscle obtained in vivo by a simplified method using [3H]proline". Biochem J. 206 (3): 535–44. PMC 1158621. PMID 7150261.
  3. Bagnato G, Harari S (2015). "Cellular interactions in the pathogenesis of interstitial lung diseases". Eur Respir Rev. 24 (135): 102–14. doi:10.1183/09059180.00003214. PMID 25726561.
  4. Ren Y, Guo L, Tang X, Apparsundaram S, Kitson C, Deguzman J; et al. (2013). "Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells". Microvasc Res. 85: 59–67. doi:10.1016/j.mvr.2012.10.004. PMID 23084965.
  5. 5.0 5.1 Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA (2011). "Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension". Arthritis Rheum. 63 (3): 783–94. doi:10.1002/art.30159. PMC 3139818. PMID 21360508.
  6. Andersson CK, Mori M, Bjermer L, Löfdahl CG, Erjefält JS (2010). "Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease". Am J Respir Crit Care Med. 181 (3): 206–17. doi:10.1164/rccm.200906-0932OC. PMID 19926870.
  7. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M; et al. (2004). "Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis". Am J Respir Crit Care Med. 169 (11): 1203–8. doi:10.1164/rccm.200308-1111OC. PMID 14754760.
  8. Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE, Geraci MW; et al. (2004). "Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis". Am J Respir Crit Care Med. 170 (3): 242–51. doi:10.1164/rccm.200308-1151OC. PMID 15117744.
  9. Königshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, Seeger W; et al. (2008). "Functional Wnt signaling is increased in idiopathic pulmonary fibrosis". PLoS One. 3 (5): e2142. doi:10.1371/journal.pone.0002142. PMC 2374879. PMID 18478089.
  10. Lam AP, Flozak AS, Russell S, Wei J, Jain M, Mutlu GM; et al. (2011). "Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation". Am J Respir Cell Mol Biol. 45 (5): 915–22. doi:10.1165/rcmb.2010-0113OC. PMC 3262680. PMID 21454805.
  11. Wygrecka M, Dahal BK, Kosanovic D, Petersen F, Taborski B, von Gerlach S; et al. (2013). "Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-α/Raf-1/p44/42 signaling pathway". Am J Pathol. 182 (6): 2094–108. doi:10.1016/j.ajpath.2013.02.013. PMID 23562441.
  12. Yasuoka H, Hsu E, Ruiz XD, Steinman RA, Choi AM, Feghali-Bostwick CA (2009). "The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms". Am J Pathol. 175 (2): 605–15. doi:10.2353/ajpath.2009.080991. PMC 2716960. PMID 19628764.
  13. Bhattacharyya S, Wu M, Fang F, Tourtellotte W, Feghali-Bostwick C, Varga J (2011). "Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy". Matrix Biol. 30 (4): 235–42. doi:10.1016/j.matbio.2011.03.005. PMC 3135176. PMID 21511034.
  14. Sun Z, Gong X, Zhu H, Wang C, Xu X, Cui D; et al. (2014). "Inhibition of Wnt/β-catenin signaling promotes engraftment of mesenchymal stem cells to repair lung injury". J Cell Physiol. 229 (2): 213–24. doi:10.1002/jcp.24436. PMID 23881674.
  15. Ruiz XD, Mlakar LR, Yamaguchi Y, Su Y, Larregina AT, Pilewski JM; et al. (2012). "Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis". PLoS One. 7 (8): e43049. doi:10.1371/journal.pone.0043049. PMC 3416749. PMID 22900087.
  16. Nho RS, Peterson M, Hergert P, Henke CA (2013). "FoxO3a (Forkhead Box O3a) deficiency protects Idiopathic Pulmonary Fibrosis (IPF) fibroblasts from type I polymerized collagen matrix-induced apoptosis via caveolin-1 (cav-1) and Fas". PLoS One. 8 (4): e61017. doi:10.1371/journal.pone.0061017. PMC 3620276. PMID 23580232.
  17. Mubarak KK, Montes-Worboys A, Regev D, Nasreen N, Mohammed KA, Faruqi I; et al. (2012). "Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis". Eur Respir J. 39 (1): 133–40. doi:10.1183/09031936.00141010. PMID 21737551.
  18. Nasreen N, Mohammed KA, Mubarak KK, Baz MA, Akindipe OA, Fernandez-Bussy S; et al. (2009). "Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro". Am J Physiol Lung Cell Mol Physiol. 297 (1): L115–24. doi:10.1152/ajplung.90587.2008. PMC 2711818. PMID 19411308.
  19. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP; et al. (2008). "Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis". Arthritis Rheum. 58 (9): 2854–65. doi:10.1002/art.23791. PMC 2770094. PMID 18759267.
  20. Thannickal VJ, Horowitz JC (2006). "Evolving concepts of apoptosis in idiopathic pulmonary fibrosis". Proc Am Thorac Soc. 3 (4): 350–6. doi:10.1513/pats.200601-001TK. PMC 2231523. PMID 16738200.
  21. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002). "Myofibroblasts and mechano-regulation of connective tissue remodelling". Nat Rev Mol Cell Biol. 3 (5): 349–63. doi:10.1038/nrm809. PMID 11988769.
  22. Castella LF, Buscemi L, Godbout C, Meister JJ, Hinz B (2010). "A new lock-step mechanism of matrix remodelling based on subcellular contractile events". J Cell Sci. 123 (Pt 10): 1751–60. doi:10.1242/jcs.066795. PMID 20427321.
  23. Capelli A, Di Stefano A, Gnemmi I, Donner CF (2005). "CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis". Eur Respir J. 25 (4): 701–7. doi:10.1183/09031936.05.00082604. PMID 15802346.
  24. Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM; et al. (2004). "The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis". J Immunol. 173 (7): 4692–8. PMID 15383605.
  25. Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A; et al. (2008). "Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis". Int J Biochem Cell Biol. 40 (10): 2129–40. doi:10.1016/j.biocel.2008.02.012. PMID 18374622.
  26. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C; et al. (2005). "CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury". Am J Pathol. 166 (3): 675–84. doi:10.1016/S0002-9440(10)62289-4. PMC 1780139. PMID 15743780.
  27. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G (2007). "The myofibroblast: one function, multiple origins". Am J Pathol. 170 (6): 1807–16. doi:10.2353/ajpath.2007.070112. PMC 1899462. PMID 17525249.
  28. Lohmann-Matthes ML, Steinmüller C, Franke-Ullmann G (1994). "Pulmonary macrophages". Eur Respir J. 7 (9): 1678–89. PMID 7995399.
  29. Wolters PJ, Collard HR, Jones KD (2014). "Pathogenesis of idiopathic pulmonary fibrosis". Annu Rev Pathol. 9: 157–79. doi:10.1146/annurev-pathol-012513-104706. PMC 4116429. PMID 24050627.
  30. Gross TJ, Hunninghake GW (2001). "Idiopathic pulmonary fibrosis". N Engl J Med. 345 (7): 517–25. doi:10.1056/NEJMra003200. PMID 11519507.

Template:WH Template:WS [[Category:Primary Care]